The Challenge of Measuring Treatment Response in oGVHD Trials
Clinical trials in oGVHD face a difficult question: what does improvement mean?
In some diseases, a single laboratory value or imaging finding can define response. oGVHD is more complex. It can involve symptoms, ocular surface staining, tear production, tear stability, conjunctival disease, corneal epithelial integrity, eyelid changes, meibomian gland function, inflammation, fibrosis, and quality of life.
A patient may feel better while some clinical signs remain. Another patient may show improved staining but still experience pain or light sensitivity. A therapy may improve tear-film behavior without immediately reversing tissue damage. A treatment may reduce inflammation but not fully restore gland function.
This creates challenges for trial design. Symptoms are essential because they reflect what the patient experiences. Dryness, burning, grittiness, pain, watering, light sensitivity, and visual fluctuation can determine whether a person can work, read, drive, sleep, or tolerate daily environments.
Clinical signs are also essential. Ocular surface staining, Schirmer testing, tear-film stability, eyelid findings, conjunctival scarring, corneal epithelial status, and other measures help clinicians understand visible disease and risk.
Patient-reported outcomes add another dimension. They can help measure function and quality of life, not just clinical appearance. In a disease that can disrupt daily living, that matters.
Biomarkers and imaging may eventually strengthen oGVHD trials by showing whether a therapy changes underlying biology. That could help distinguish temporary symptom relief from disease modification.
The TFOS DEWS II Clinical Trial Design Report, although focused on dry eye disease broadly, highlights a central challenge relevant to ocular surface research: the lack of correlation between signs and symptoms has complicated trial development. oGVHD adds transplant-related immunology, fibrosis, and systemic disease context to that already difficult measurement problem.
Good oGVHD trial design must account for disease heterogeneity. Patients may differ by transplant history, systemic GVHD status, ocular severity, treatment history, tear production, meibomian gland involvement, corneal damage, and conjunctival scarring. This makes patient selection and endpoint choice critical.
For patients and advocates, understanding endpoints makes research easier to interpret. A positive result may mean symptom improvement, sign improvement, biomarker change, reduced treatment burden, or some combination. The details matter.
Better measurement is not an academic issue. It is central to progress.
In oGVHD, the future of therapy depends partly on the future of endpoints.
This article is for educational purposes only and is not medical advice.
Sources:
- Novack GD, Asbell P, Barabino S, et al. “TFOS DEWS II Clinical Trial Design Report.” The Ocular Surface, 2017.
https://tfosdewsreport.org/report-clinical_trial_design/163_36/en/ - Wolffsohn JS, Arita R, Chalmers R, et al. “TFOS DEWS II Diagnostic Methodology Report.” The Ocular Surface, 2017.
https://www.tfosdewsreport.org/public/images/TFOS_DEWS_II_Diagnostic_method.pdf - Jagasia MH, Greinix HT, Arora M, et al. “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report.” Biology of Blood and Marrow Transplantation, 2015.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4329079/ - Micera A, et al. “Molecular Biomarkers in Ocular Graft-versus-Host Disease: A Systematic Review.” Biomolecules, 2024.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10813443/
